Sy Mukherjee
Fortune
New York, NY, United States
Contact Sy
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
Recent articles by Sy:
Can Disturbing Graphics Scare People Off Cigarettes?
The FDA is proposing European-style, graphic warnings on cigarette packs to discourage smoking. But will it work? → Read More
A Promising Pair of Ebola Drugs Raises Hopes in Africa
Experimental treatments from Regeneron and Ridgeback Biotherapeutics will now be offered to all Ebola patients in the Congo. → Read More
Novartis Defends $2.1 Million Gene Therapy After FDA Data Manipulation Claims
The FDA said Tuesday that Novartis knew of data inaccuracies in its application for Zolgensma, a gene therapy with a $2.1 million list price. → Read More
Legislating Social Media Addiction: Brainstorm Health
There’s a presidential primary debate on tonight (and I imagine at least a few readers will be checking in on it, given an expected focus on health care). But let’s check in on a more low-key, and likely quixotic, policy quest aligned with the digital health space. A freshman U.S. Senator (Josh Hawley, a Missouri […] → Read More
A $43 Billion Biotech Now Has a Female CEO
Reshma Kewalramani is taking the reins at Vertex Pharmaceuticals from industry veteran Jeff Leiden. → Read More
How CVS Wants to Link Social Care With Health Care
CVS wants to get to the source of social care needs that can affect people's health well outside the doctor's office. → Read More
The Heat Is On. Stay Cool
Remember to keep cool during the upcoming heat wave swamping much of the U.S. → Read More
Protect at All Costs: How the Maker of the World’s Bestselling Drug Keeps Prices Sky-High
Humira has turned AbbVie into a global pharma giant—and the company has aggressively blocked competition to protect its sales. How a blockbuster medication became a case study in what’s killing drug innovation. You may not have any of the conditions Humira treats. But chances are, you’ve heard of it. AbbVie’s flagship therapy, a medicine used to treat a slew of […] → Read More
Genentech’s Deal Spree: Brainstorm Health
Good afternoon, readers. We’re hunkered down and closing the upcoming issue of Fortune today. But in the meantime, I hope you’ll follow along with my colleagues’ outstanding coverage of the equally-outstanding Fortune Brainstorm Tech conference currently taking place in Aspen. And a note below on Genentech’s “hat trick” of deals. Read on for the day’s […] → Read More
The Health Care Leaders in Fortune's 40 Under 40
Meet the health care leaders in Fortune's latest 40 Under 40 list of young entrepreneurs. → Read More
3 Drug Giants Win a Legal Victory Against Trump—For Now
Merck, Amgen, and Eli Lilly have successfully blocked the Trump administration's requirement they post drug prices in T.V. ads. → Read More
Can a Monthly Injection Treat HIV?
GlaxoSmithKline announced that Viiv Healthcare, its HIV-focused arm, will launch trials of a long-acting, once-monthly HIV treatment in U.S. clinics. → Read More
Facebook's Health Crackdown: Brainstorm Health
Facebook said Tuesday it's trying to crack down on misleading health claims on its platform. → Read More
uBiome Has a Leadership Problem Amid FBI Woes: Brainstorm Health
The interim CEO of uBiome is stepping down as the company continues to grapple with an FBI investigation. → Read More
Meet Andrew Yang, the Democratic Candidate Who Wants to Give You $1,000 Each Month
Fortune interviewed Andrew Yang, the long shot presidential hopeful who will be on stage for the Democratic debate, on UBI and other issues. → Read More
Digital Health Startup Omada Snags Another $73 Million in Funding: Brainstorm Health
Omada Health raised $73 million at a reported $600 million valuation for its digital diabetes prevention platform. → Read More
Digital Health Startup Omada Snags Another $73 Million in Funding: Brainstorm Health
Omada Health raised $73 million at a reported $600 million valuation for its digital diabetes prevention platform. → Read More
What the $63 Billion AbbVie Allergan Deal Says About the Drug Industry: Brainstorm Health
AbbVie's acquisition of the Botox maker isn't a great reflection on the state of big pharma innovation. → Read More
What AbbVie's $63 Billion Deal to Buy Allergan Says About the Drug Industry
AbbVie, maker of the world's best-selling drug, is buying Botox maker Allergan in a blockbuster deal. Here's what that says about the state of biopharma. → Read More
What the $63 Billion AbbVie Allergan Deal Says About the Drug Industry: Brainstorm Health
AbbVie's acquisition of the Botox maker isn't a great reflection on the state of big pharma innovation. → Read More